It has recently been investigated the role of CaSR in lethal prostate cancers, where higher CaSR tumour expression was associated with an approximately 2-fold higher risk for lethal progression, independently of Gleason grade and pathological stage [46]. This evidence concerns the gene CASR and prostate cancer.